News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Oxygen Biotherapeutics, Inc. Builds New Relationships for Dermacyte Products and Traumatic Brain Injury Clinical Trials
May 19, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
DURHAM, N.C., May 19, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) announced today that the Company has formalized working relationships with an international cosmetic company and a site monitoring company.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Tenax Therapeutics
MORE ON THIS TOPIC
Podcast
Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening
May 6, 2026
·
1 min read
·
Heather McKenzie
Earnings
Pfizer is a 2029 story but Q126 lays foundation for growth
May 5, 2026
·
3 min read
·
Annalee Armstrong
Layoffs
BioNTech moves to close multiple manufacturing plants, affecting 1,860 jobs
May 5, 2026
·
2 min read
·
Nick Paul Taylor
Earnings
Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat
May 5, 2026
·
2 min read
·
Annalee Armstrong
